Evidence map›Paper›PMID 29535375›Full record

ArticleGene therapy2018

MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates.

Alan H Nagahara, Bayard R Wilson, Iryna Ivasyk, Imre Kovacs, Saytam Rawalji, John R Bringas, Phillip J Pivirotto, Waldy San Sebastian, Lluis Samaranch, Krystof S Bankiewicz and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Disruption of BDNF signalling in neuropathologies.Biochemical Society transactions · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Neurosurgical gene therapy for central nervous system diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Alan H NagaharaDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA.
Bayard R WilsonDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA.
Iryna IvasykDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA.
Imre KovacsDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA.
Saytam RawaljiDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA.
John R BringasDepartment of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94103, USA.
Phillip J PivirottoDepartment of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94103, USA.
Waldy San SebastianDepartment of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94103, USA.
Lluis SamaranchDepartment of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94103, USA.ORCID http://orcid.org/0000-0001-8151-473X
Krystof S BankiewiczDepartment of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94103, USA. Krystof.Bankiewicz@ucsf.edu.
Mark H TuszynskiDepartment of Neurosciences, University of California-San Diego, La Jolla, CA, 92093, USA. mtuszynski@ucsd.edu.
University of California San Diego · USUniversity of California, San Francisco · USSan Francisco VA Medical Center · US

Funding

Viral VectorsP01AG010435 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 1991 to 2014
$20.9M
A Translational Program of BDNF Gene Delivery in Alzheimer's DiseaseU01AG043416 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 2014 to 2019
$4.6M
NIA NIH HHS P01 AG010435NIA NIH HHS U01 AG043416
6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) gene delivery to the entorhinal cortex is a candidate for treatment of Alzheimer's disease (AD) to reduce neurodegeneration that is associated with memory loss. Accurate targeting of the entorhinal cortex in AD is complex due to the deep and atrophic state of this brain region. Using MRI-guided methods with convection-enhanced delivery, we were able to accurately and consistently target AAV2-BDNF delivery to the entorhinal cortex of non-human primates; 86 ± 3% of transduced cells in the targeted regions co-localized with the neuronal marker NeuN. The volume of AAV2-BDNF (3 × 10

Indexed as

AnimalsBrain-Derived Neurotrophic FactorContrast MediaDependovirusEntorhinal CortexFemaleGadoliniumGenetic VectorsGreen Fluorescent ProteinsHeterocyclic CompoundsHippocampusMacaca fascicularisMacaca mulattaMagnetic Resonance ImagingMaleNeuronsBrain-Derived Neurotrophic FactorContrast MediaGadoliniumgadoteridolGreen Fluorescent ProteinsHeterocyclic CompoundsOrganometallic Compounds

Identifiers

PMID29535375
PMCPMC5924461
OpenAlexW2791712907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.